Orlistat-d3

Orlistat-d3 is a deuterated labeled Orlistat[1]. Orlistat (Tetrahydrolipstatin) is a well-known irreversible inhibitor of pancreatic and gastric lipases. Orlistat is also an inhibitor of fatty acid synthase (FASN), is used orally for long-term research of obesity[2]. Anti-atherosclerotic effect[3].

Product Specifications

CAS Number

[1356930-46-5]

Product Name Alternative

Tetrahydrolipstatin-d3; Ro-18-0647-d3

UNSPSC

12352005

Target

Apoptosis; Fatty Acid Synthase (FASN) ; Isotope-Labeled Compounds

Type

Isotope-Labeled Compounds

Related Pathways

Apoptosis; Metabolic Enzyme/Protease; Others

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease

Purity

0.99

Smiles

O=C1[C@@H](CCCCCC)[C@H](C[C@@H](OC([C@@H](NC([H])=O)CC(C)C([2H])([2H])[2H])=O)CCCCCCCCCCC)O1

Molecular Formula

C29H50D3NO5

Molecular Weight

498.75

References & Citations

[1]Giorgia Cioccoloni, et al. Influence of fatty acid synthase inhibitor orlistat on the DNA repair enzyme O6-methylguanine-DNA methyltransferase in human normal or malignant cells in vitro. Int J Oncol. 2015 Aug;47 (2) :764-72.|[2]Zaidatul Akmal Othman, et al. Anti-Atherogenic Effects of Orlistat on Obesity-Induced Vascular Oxidative Stress Rat Model. Antioxidants (Basel) . 2021 Feb 6;10 (2) :251.|[3]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53 (2) :211-216.